Kiran Mazumdar-Shaw Bets Big On H2 Growth After Profit Slumps By 52%
NDTV Profit · 05 Nov 2026 · 19 min
Management interview of Biocon Ltd (BIOCON), with 5 key numbers discussed.
- Kiran Mazumdar-Shaw, Executive Chairperson, Biocon
Biocon maintained its outlook for a slow first half followed by a strong second half in FY27. Executive Chairperson Kiran Mazumdar-Shaw noted that almost 5% of revenue spilled into the next quarter due to logistics reasons. The company expects strong double-digit revenue growth in H2, driven by insulins (glargine and aspart), aflibercept, and pertuzumab launches in Europe and Brazil. EBITDA margins are guided in the mid-20s range, supported by higher volumes and operational efficiencies.